John Schreiber, MD, FAES

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Neurocrine Biosciences
    Topic:
    SCN8A
    Date added:
    08/20/2024
    Date updated:
    08/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Denali Therapeutics
    Topic:
    Genetic Epilepsy
    Date added:
    08/20/2024
    Date updated:
    08/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Stoke Therapeutics
    Topic:
    Dravet syndrome
    Date added:
    08/20/2024
    Date updated:
    08/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    UCB
    Topic:
    fenfluramine speaker
    Date added:
    08/20/2024
    Date updated:
    08/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Marinus
    Topic:
    ganaxolone speaker
    Date added:
    08/20/2024
    Date updated:
    08/20/2024
Return to Oct. 4, 2024 Epilepsy Conference: Contemporary Management Trends in Intractable Epilepsy